ChemoCentryx
San Carlos
About ChemoCentryx
ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $634.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2020)
- Ticker: nasdaq:CCXI
- Website: chemocentryx.com
- Phone: +1 650 210 2900
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/chemocentryx-8441 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.